# US 2015/0104504 A1 · Compositions of statins and omega-3 fatty acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104504 A1
- Document ID: US20150104504A1
- Status: Published application
- Kind: A1
- Application number: 14/399,355
- Filed: 2013-05-07
- Published: 2015-04-16
- Earliest claimed: 2012-05-07
- Assignees: Omthera Pharmaceuticals, Inc.
- Applicants: Omthera Pharmaceuticals, Inc.
- Inventors: Bernardus Machielse; Timothy J. Maines; Michael H. Davidson; Bharat M. Mehta
- Web page: https://patentgrep.com/patent/US20150104504A1

## CPC

- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.

## Claims

### Claim 1

A pharmaceutical composition comprising a statin dissolved in a PUFA free acid solvent system.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein no more than about 10% by weight of the statin is undissolved in the solvent system.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the statin is dissolved in the PUFA free acid solvent system at a concentration of at least about 5 mg statin per gram solvent system.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the statin is dissolved in the PUFA free acid solvent system at a concentration of at least about 7.5 mg/g.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the statin is dissolved in the PUFA free acid solvent system at a concentration of at least about 10 mg/g.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the statin is dissolved in the PUFA free acid solvent system at a concentration of at least about 20 mg/g.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the statin is selected from the group consisting of: pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, rosuvastatin, and pitavastatin.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the statin is rosuvastatin.

### Claim 9 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the statin is atorvastatin.

### Claim 10 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the statin is simvastatin.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the PUFA free acid solvent system comprises EPA.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein EPA is present in the PUFA free acid solvent system in an amount of at least about 40% (a/a).

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, wherein DHA is present in the PUFA free acid solvent system in an amount of at least about 13% (a/a).

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein DPA (C22:5 n-3) is present in the PUFA free acid solvent system in an amount of at least about 1% (a/a).

### Claim 15 (depends on 14)

The pharmaceutical composition according to claim 14, wherein the PUFA free acid solvent system comprises about 45% (a/a) to about 65% (a/a) EPA, about 15% (a/a) to about 25% (a/a) DHA, and about 1% (a/a) to about 8% (a/a) DPA (C22:5 n-3).

### Claim 16 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the PUFA free acid solvent system comprises no more than about 10% (a/a) omega-6 fatty acids in free acid form.

### Claim 17 (depends on 1)

An oral unit dosage form, wherein the dosage form comprises a capsule, the capsule containing a pharmaceutical composition according to claim 1.

### Claim 18 (depends on 17)

The oral unit dosage form according to claim 17, wherein the capsule comprises gelatin.

### Claim 19 (depends on 18)

The oral unit dosage form according to claim 18, wherein the capsule is a soft gelatin capsule.

### Claim 20 (depends on 19)

The oral unit dosage form of claim 19, wherein the soft gelatin capsule comprises Type A gelatin.

### Claim 21 (depends on 20)

The oral unit dosage form of claim 20, wherein at least about 1% (w/w) of the gelatin is Type A gelatin.

### Claim 22 (depends on 21)

The oral unit dosage form of claim 21, wherein the type A gelatin is porcine type A gelatin.

### Claim 23 (depends on 17)

The oral unit dosage form of claim 17, further comprising a coating on the exterior of the capsule.

### Claim 24 (depends on 23)

The oral unit dosage form according to claim 23, wherein the coating is a pH-sensitive enteric coating.

### Claim 25 (depends on 23)

The oral unit dosage form according to claim 23, wherein the coating is a pH-insensitive coating.

### Claim 26 (depends on 25)

The oral unit dosage form according to claim 25, wherein the coating is a poly(ethylacrylate-methylacrylate) copolymer.

### Claim 27 (depends on 26)

The oral unit dosage form according to claim 26, wherein the coating is Eudragit NE-30D.

### Claim 28 (depends on 17)

The oral unit dosage form according to claim 17, wherein the capsule contains about 1 to about 100 mg of a statin dissolved in about 500 mg to about 1 g of a PUFA free acid solvent system.

### Claim 29 (depends on 28)

The oral unit dosage form according to claim 28, wherein the capsule contains about 2.5 mg to about 40 mg of a statin dissolved in about 1 g of a PUFA free acid solvent system.

### Claim 30 (depends on 17)

The oral unit dosage form of claim 17, wherein the statin is rosuvastatin.

### Claim 31 (depends on 17)

The oral unit dosage form of claim 17, wherein the statin is atorvastatin.

### Claim 32 (depends on 17)

The oral unit dosage form of claim 17, wherein the statin is simvastatin.

### Claim 33 (depends on 1)

A method of treating a blood lipid disorder, comprising administering a pharmaceutical composition according to claim 1 to a subject with a blood lipid disorder in an amount and for a duration sufficient to treat the blood lipid disorder.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the blood lipid disorder is selected from the group consisting of: hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, mixed dyslipidemia, and atherosclerosis.

### Claim 35 (depends on 33)

The method according to claim 33, wherein the method comprises administering at least 2 g of the pharmaceutical composition daily.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the method comprises administering at least about 10 mg of statin daily.

### Claim 37 (depends on 33)

The method according to claim 33, wherein the PUFA free acid solvent system of the pharmaceutical composition comprises at least about 45% (a/a) EPA.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the statin in the pharmaceutical composition is rosuvastatin.

### Claim 39 (depends on 37)

The method according to claim 37, wherein the statin in the pharmaceutical composition is atorvastatin.

### Claim 40 (depends on 37)

The method according to claim 37, wherein the statin in the pharmaceutical composition is simvastatin.
